Profile data is unavailable for this security.
About the company
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
- Revenue in CAD (TTM)112.06m
- Net income in CAD-9.49m
- Incorporated1995
- Employees103.00
- LocationTheratechnologies Inc2015 Peel Street, 11th FloorMONTREAL H3A 1T8CanadaCAN
- Phone+1 (514) 336-7800
- Fax+1 (514) 331-9691
- Websitehttps://www.theratech.com/